IL-23 and Th17 Disease in Inflammatory Arthritis

IL-23 and Th17 Disease in Inflammatory Arthritis

IL-23, which is composed of p19 and p40 subunits, is a proinflammatory cytokine that contributes to the formation and maintenance of Th17 cells in inflammatory autoimmune diseases. IL-23 is a human osteoclastogenic cytokine and anti-IL-23 antibody attenuates paw volume and joint destruction in CIA r...

Full description

Bibliographic Details
Main Authors:	Toru Yago, Yuki Nanke, Manabu Kawamoto, Tsuyoshi Kobashigawa, Hisashi Yamanaka, Shigeru Kotake
Format:	Article
Language:	English
Published:	MDPI AG 2017-08-01
Series:	Journal of Clinical Medicine
Subjects:	IL-23 rheumatoid arthritis spondyloarthritis ankylosing spondylitis psoriatic arthritis
Online Access:	https://www.mdpi.com/2077-0383/6/9/81

Similar Items

Comorbidities in inflammatory joint and spine diseases in XXI century
by: I Z Gaydukova, et al.
Published: (2018-12-01)

IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS
by: E. L. Nasonov, et al.
Published: (2019-09-01)

IL-33 Gene Polymorphisms as Potential Biomarkers of Disease Susceptibility and Response to TNF Inhibitors in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Patients
by: Milena Iwaszko, et al.
Published: (2021-06-01)

Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis)
by: Cauli A, et al.
Published: (2015-10-01)

Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis
by: Dennis McGonagle, et al.
Published: (2021-03-01)

The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis
by: Hiroyuki Tsukazaki, et al.
Published: (2020-09-01)

NEW POSSIBILITIES OF PHARMACOTHERAPY FOR IMMUNOINFLAMMATORY RHEUMATIC DISEASES: A FOCUS ON INHIBITORS OF INTERLEUKIN-17
by: E. L. Nasonov
Published: (2017-03-01)

Comparative analysis between ankylosing spondylitis and axial psoriatic arthritis patients
by: Marwa Mahmoud Abdelaziz, et al.
Published: (2022-01-01)

Diagnosis of spondyloarthritis: should we need new criteria?
by: I. Z. Gaidukova, et al.
Published: (2015-03-01)

«TREAT-TO-TARGET» (T2T) STRATEGY IN SPONDYLOARTHRITIS
by: Sh. F. Erdes
Published: (2014-06-01)

Prevalence of spondyloarthritis and its subtypes - are they really comparable?
by: Zlatković-Švenda Mirjana I., et al.
Published: (2019-01-01)

Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study
by: Karin Bengtsson, et al.
Published: (2017-05-01)

Demographic, clinical and radiological characteristics of seronegative spondyloarthritis Egyptian patients: A rheumatology clinic experience in Mansoura
by: Adel Abdelsalam, et al.
Published: (2017-04-01)

Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis
by: Takacs P, et al.
Published: (2019-01-01)

Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study
by: Joshua L. Lee, et al.
Published: (2018-08-01)

Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients
by: Chen HH, et al.
Published: (2017-05-01)

Changing the concept of spondyloarthritis: Characteristics of teaching when changing the paradigm in a particular area of medical knowledge
by: I. Z. Gaydukova, et al.
Published: (2017-04-01)

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
by: M. Rossini, et al.
Published: (2015-03-01)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
by: Vandana Bhushan, et al.
Published: (2021-09-01)

Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies
by: Katarzyna Bogunia-Kubik, et al.
Published: (2021-07-01)

Use of antidepressants and benzodiazepine-related hypnotics before and after initiation of TNF-α inhibitors or non-biological systemic treatment in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
by: Philip Brenner, et al.
Published: (2020-02-01)

Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis
by: Santhi Mantravadi, et al.
Published: (2020-09-01)

Ankylosing spondylitis and psoriatic arthritis: clinical and economic consequences of the use of etanercept
by: Viola Sacchi, et al.
Published: (2010-06-01)

Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register
by: Paloma Vela, et al.
Published: (2020-06-01)

Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line
by: Svedbom A, et al.
Published: (2017-01-01)

Bone phenotypes in rheumatology – there is more to bone than just bone
by: Christian S. Thudium, et al.
Published: (2020-11-01)

Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion
by: Jozélio Freire de Carvalho, et al.
Published: (2018-08-01)

Association Between Nursing Support Levels and Effectiveness of Golimumab in the Management of Patients with Rheumatologic Diseases
by: Hermine Leroi, et al.
Published: (2020-05-01)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
by: Lubrano E, et al.
Published: (2016-10-01)

Imaging of juvenile spondyloarthritis. Part I: Classifications and radiographs
by: Iwona Sudoł-Szopińska, et al.
Published: (2017-09-01)

Classifications and imaging of juvenile spondyloarthritis
by: Iwona Sudoł-Szopińska, et al.
Published: (2018-09-01)

A case of rheumatoid spondyloarthritis!
by: Sujatha N, et al.
Published: (2019-01-01)

A case of psoriatic arthritis, with joint involvement preceding skin involvement, successfully treated with adalimumab (80 mg every other week)
by: Yuki Nanke, et al.
Published: (2019-04-01)

Mediterranean diet in axial spondyloarthritis: an observational study in an Italian monocentric cohort
by: Francesca Ometto, et al.
Published: (2021-08-01)

Spectrum of spondyloarthritis
by: Himanshu Pathak, et al.
Published: (2020-01-01)

Coexistence of rheumatoid arthritis and ankylosing spondylitis
by: Tacjana Anna Barczyńska, et al.
Published: (2015-12-01)

The frequency and structure of comorbid infections in patients with spondyloarthritis (preliminary own data)
by: M. M. Baranova, et al.
Published: (2021-03-01)

PALLIATIVE CARE IN SPONDYLOARTHRITIS: IS THERE A NEED FOR THIS?
by: A. P. Rebrov, et al.
Published: (2015-04-01)

Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study
by: Muhammad Haroon, et al.
Published: (2018-04-01)

Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases
by: Laura Cometi, et al.
Published: (2020-05-01)